Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis

Objective Tolvaptan was first approved for use for cirrhosis in Japan in September 2013. The aim of the study was to examine the effect of tolvaptan, a vasopressin V2 receptor antagonist, on the prognosis of cirrhosis. Methods The effect of tolvaptan was evaluated in 26 patients with cirrhosis treat...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Intern Med
Glavni autori: Iwamoto, Takuya, Maeda, Masaki, Hisanaga, Takuro, Saeki, Issei, Fujisawa, Koichi, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Format: Artigo
Jezik:Inglês
Izdano: The Japanese Society of Internal Medicine 2016
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5109555/
https://ncbi.nlm.nih.gov/pubmed/27746425
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items